Abbott Laboratories (ABT.N)
ABT.N on New York Stock Exchange
58.31USD
24 Apr 2018
58.31USD
24 Apr 2018
Change (% chg)
$-0.53 (-0.90%)
$-0.53 (-0.90%)
Prev Close
$58.84
$58.84
Open
$59.01
$59.01
Day's High
$59.06
$59.06
Day's Low
$57.67
$57.67
Volume
1,555,898
1,555,898
Avg. Vol
1,916,233
1,916,233
52-wk High
$64.60
$64.60
52-wk Low
$42.88
$42.88
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.71 | December | 25 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 8 | 8 | 8 | 7 |
| (2) OUTPERFORM | 7 | 8 | 8 | 8 |
| (3) HOLD | 4 | 4 | 4 | 5 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.79 | 1.80 | 1.80 | 1.90 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 16 | 7,759.87 | 7,817.78 | 7,678.00 | 6,947.60 |
| Quarter Ending Sep-18 | 16 | 7,844.06 | 7,949.00 | 7,742.00 | 7,011.94 |
| Year Ending Dec-18 | 19 | 31,081.40 | 31,285.60 | 30,797.00 | 27,591.40 |
| Year Ending Dec-19 | 19 | 32,940.70 | 33,299.00 | 32,422.00 | 29,150.70 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 18 | 0.71 | 0.72 | 0.70 | 0.67 |
| Quarter Ending Sep-18 | 18 | 0.74 | 0.77 | 0.72 | 0.74 |
| Year Ending Dec-18 | 21 | 2.86 | 2.90 | 2.85 | 2.76 |
| Year Ending Dec-19 | 21 | 3.22 | 3.31 | 3.12 | 3.07 |
| LT Growth Rate (%) | 7 | 11.86 | 13.80 | 7.10 | 10.90 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 7,285.94 | 7,390.00 | 104.06 | 1.43 |
| Quarter Ending Dec-17 | 7,385.90 | 7,589.00 | 203.10 | 2.75 |
| Quarter Ending Sep-17 | 6,716.81 | 6,829.00 | 112.19 | 1.67 |
| Quarter Ending Jun-17 | 6,634.66 | 6,637.00 | 2.34 | 0.04 |
| Quarter Ending Mar-17 | 6,151.19 | 6,335.00 | 183.81 | 2.99 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | 0.58 | 0.59 | 0.01 | 1.71 |
| Quarter Ending Dec-17 | 0.73 | 0.74 | 0.01 | 1.07 |
| Quarter Ending Sep-17 | 0.65 | 0.66 | 0.01 | 1.18 |
| Quarter Ending Jun-17 | 0.61 | 0.62 | 0.01 | 2.48 |
| Quarter Ending Mar-17 | 0.43 | 0.48 | 0.05 | 11.63 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 7,759.87 | 7,711.42 | 7,711.55 | 7,708.96 | 6,947.60 |
| Quarter Ending Sep-18 | 7,844.06 | 7,829.76 | 7,835.19 | 7,833.38 | 7,011.94 |
| Year Ending Dec-18 | 31,081.40 | 30,847.40 | 30,855.20 | 30,847.10 | 27,591.40 |
| Year Ending Dec-19 | 32,940.70 | 32,764.50 | 32,781.20 | 32,771.40 | 29,150.70 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 0.71 | 0.71 | 0.71 | 0.71 | 0.67 |
| Quarter Ending Sep-18 | 0.74 | 0.75 | 0.75 | 0.75 | 0.74 |
| Year Ending Dec-18 | 2.86 | 2.86 | 2.85 | 2.85 | 2.76 |
| Year Ending Dec-19 | 3.22 | 3.21 | 3.21 | 3.21 | 3.07 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 13 | 2 | 13 | 2 |
| Quarter Ending Sep-18 | 8 | 7 | 8 | 7 |
| Year Ending Dec-18 | 16 | 3 | 16 | 3 |
| Year Ending Dec-19 | 16 | 2 | 16 | 2 |
| Earnings | ||||
| Quarter Ending Jun-18 | 7 | 6 | 6 | 6 |
| Quarter Ending Sep-18 | 6 | 7 | 6 | 7 |
| Year Ending Dec-18 | 9 | 1 | 10 | 1 |
| Year Ending Dec-19 | 6 | 2 | 8 | 2 |
Earnings vs. 
Estimates- BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables
- Factbox - U.S. companies with exposure to Russia
- FACTBOX-U.S. companies with exposure to Russia
- Abbott sticks to earlier forecasts, disappoints investors
- UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors